KEPPRA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8802142 | UCB INC | Pharmaceutical compositions comprising levetiracetam and process for their preparation |
Jun, 2031
(7 years from now) | |
|
US8802142 (Pediatric) | UCB INC | Pharmaceutical compositions comprising levetiracetam and process for their preparation |
Dec, 2031
(7 years from now) | |
Keppra is owned by Ucb Inc.
Keppra contains Levetiracetam.
Keppra has a total of 2 drug patents out of which 0 drug patents have expired.
Keppra was authorised for market use on 06 January, 2006.
Keppra is available in tablet;oral dosage forms.
The generics of Keppra are possible to be released after 07 December, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 16, 2014 |
| Pediatric Exclusivity(PED) | Jun 16, 2015 |
Drugs and Companies using
LEVETIRACETAM ingredient
Market Authorisation Date:
06 January, 2006Treatment:
NADosage:
TABLET;ORAL
How can I launch a generic of KEPPRA before its drug patent expiration?
More Information on Dosage
KEPPRA family patents
